Toppan Printing Co., Ltd.

Osaka University

Japanese Foundation for Cancer Research

Nippon Medical School Foundation

Kyushu University

Shiro Kitano

Kei Tsukamoto

Shinji Irie

Michiya Matsusaki

Hiroki Nagase

Yuki Takahashi

Takeshi Yamada

Ryohei Katayama

Akio Yamane

Satoshi Nagayama

Mashimo Nakayama

Takuma Iwai

Koki Takeda

Goro Takahashi

Atsushi Maruyama

The present invention relates to an abnormal cardiac rhythm myocardial model composed of a three-dimensional tissue containing cells including the cardiomyocytes and collagen, wherein at least a portion of the cells adheres to the collagen.

Abnormal cardiac rhythm myocardial model and method for producing same, agent for forming abnormal cardiac rhythm myocardial model, and method for evaluating drug efficacy of heart disease therapeutic

A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.

Primary culture method

A method of detecting somatic mutations of tumor marker genes includes recovering a peripheral blood mononuclear cell layer from a blood sample collected from a subject and examining whether or not a nucleic acid derived from tumor marker genes having somatic mutations is detected from DNA included in the peripheral blood mononuclear cell layer.

Method of detecting somatic mutations in tumor marker genes, and tumor status evaluation method

A method of assessing a possibility of cancerization including culturing a cell structure including normal cells and having a vascular network structure in a presence of a biological specimen from a subject, and assessing a possibility of cancerization in the subject based on a state of vessels in the cell structure after the culturing. The biological specimen is a body fluid specimen from the subject, a cell extract of cells from the subject, or a culture supernatant of cells from the subject, and the possibility of cancerization is assessed as high in the subject when a number of cells forming the vessels in the cell structure is larger than a number of cells cultured in an absence of the body fluid specimen, or when the vascular network structure in the cell structure extends.

Method and kit for assessing possibility of cancerization

A method of separating a target double-stranded nucleic acid molecule from a sample including the target double-stranded nucleic acid molecule and a non-target double-stranded nucleic acid molecule, including (1) mixing the sample, a pyrrole-imidazole-containing polyamide (first PI polyamide) modified with a first linker molecule and capable of specifically binding to a sequence of the target double-stranded nucleic acid molecule, and a carrier a modified with a first ligand capable of specifically binding and/or adsorbing to the first linker molecule such that a mixed solution is produced, (2) forming a complex A by binding the carrier a to the first PI polyamide with which the target double-stranded nucleic acid molecule is bound in the mixed solution, and (3) separating the complex A from the mixed solution.

Method and kit for concentrating target double-stranded nucleic acid molecules using a pyrrole-imidazole-containing polyamide

A method of assessing an anti-cancer drug including culturing a cell structure including cancer cells and stromal cells in a presence of at least one anti-cancer drug, and assessing an anti-cancer effect of the at least one anti-cancer drug based on a number of viable cancer cells in the cell structure after the culturing.

Anti-cancer drug assessment method

A method of producing drug resistant cells including contacting exosomes from a living organism exhibiting drug resistance with cells exhibiting no drug resistance such that drug resistant cells are formed, and culturing the drug resistant cells.

Method of preparing cells exhibiting drug resistance, method of screening anticancer drugs, and anticancer drug screening kit

Disclosed is a three-dimensional tissue comprising cells and collagen including endogenous collagen, wherein at least a portion of the cells is adhered to the collagen, and the content of the collagen is from 10 wt % to 90 wt % based on the three-dimensional tissue.

Three-dimensional tissue body, method for producing same, and formation agent for three-dimensional tissue body

The present invention relates to a method of distinguishing genotypes using PCR-PHFA including: a nucleic acid amplification step in which a mutation site-including region of a gene is amplified by a nucleic acid amplification reaction, thereby obtaining an amplification reaction solution; and a distinction step in which the amplification reaction solution obtained from the nucleic acid amplification step is mixed with a reference double-stranded nucleic acid having a specific genotype on the mutation site as well as being labeled with a labeling substance, and the mixture is subjected to a competitive strand displacement reaction, and the level of the occurrence of strand displacement is assessed so as to distinguish the identity; and the competitive strand displacement reaction is performed under a condition to suppress a polymerase extension reaction, and a genotype distinguishing kit for use in the distinct of genotypes by this method.

Growing community of inventors

Taito-ku, Japan

Shiro Kitano